Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis

  title={Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis},
  author={Penina Tarshish and Jonathan N. Tobin and Jay Bernstein and Chester M. Edelmann},
  journal={Pediatric Nephrology},
Sixty children, with biopsy diagnosed focal segmental glomerulosclerosis (FSGS) and with unremitting nephrotic syndrome despite intensive therapy with adrenocortical steroids, were randomly allocated into a clinical trial comparing prednisone, 40 mg/m2 on alternate days for a period of 12 months (control group), with the same prednisone regimen plus a 90-day course of daily cyclophosphamide, 2.5 mg/kg in a single morning dose (experimental group). One-quarter of the children in each group had… CONTINUE READING